CDA | Evidence Driven
CDA | Evidence Driven

Cabozantinib (Cabometyx) for Hepatocellular Carcinoma - Details

Details

Files
Generic Name:
Cabozantinib
Project Status:
Complete
Therapeutic Area:
HCC
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Brand Name:
Cabometyx
Project Line:
Reimbursement Review
Project Number:
PC0186-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
20 mg, 40 mg & 60 mg
Tumour Type:
Gastrointestinal
Indications:
Hepatocellular Carcinoma
Funding Request:
For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Pre Noc Submission:
Yes
Sponsor:
Ipsen Biopharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Cabozantinib (Cabometyx) HCC – pERC Final Recommendation Final Recommendation April 22, 2020 View PDF
Cabozantinib (Cabometyx) HCC – Final Economic Guidance Report Guidance Report April 22, 2020 View PDF
Cabozantinib (Cabometyx) HCC – Final Clinical Guidance Report Guidance Report April 22, 2020 View PDF
Cabozantinib (Cabometyx) HCC – pERC Initial Recommendation Initial Recommendation April 2, 2020 View PDF
Cabozantinib (Cabometyx) HCC – PAG Feedback on Initial Recommendation Feedback April 22, 2020 View PDF
Cabozantinib (Cabometyx) HCC – Manufacturer Feedback on Initial Recommendation Feedback April 22, 2020 View PDF
8. Cabozantinib (Cabometyx) HCC – Clinician Feedback on Initial Recommendation Feedback April 22, 2020 View PDF
Cabozantinib (Cabometyx) HCC – Patient Advocacy Group COI Declarations COI Declarations April 22, 2020 View PDF
Cabozantinib (Cabometyx) HCC – Clinician COI Declarations COI Declarations April 22, 2020 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 7, 2020